Verwandte Artikel zu Biomarkers, Diagnostics and Precision Medicine in the...
Biomarkers, Diagnostics and Precision Medicine in the Drug Industry: Critical Challenges, Limitations and Roadmaps for the Best Practices - Softcover
Inhaltsangabe
The high failure rate in the pharmaceutical industry has positioned biomarkers and personalized medicine in the frontline, as possible solutions. If executed right, biomarkers and companion diagnostics (CDx) can potentially help the drug industry enhance the probability of success, accelerate the time to market, and, more importantly, benefit patients by supporting accurate diagnosis and selection of the most effective and least toxic therapies. This book aims to examine the challenges and limitations in biomarkers and laboratory tests. It also offers advice on best practices to ensure proper application of biomarkers and bridges the gap between diagnostic business development claims and real-life deliverables. The book covers biomarkers for different purposes, provides examples from different technologies, which includes standard-of-care approved assays as well as for-investigational-use and for-research-use-only assays. It also includes new data for biomarkers in different therapeutic indications and offers case studies and practical examples.
This book serves as a reference to drug developers, IVD providers, clinical labs, healthcare givers, academicians, and researchers for best practices to help increase the probability of success in drug development and improve patient management.
- Provides the unique insight of an expert with extensive experience in diagnostics and clinical laboratory on one side and drug discovery and development on the other side
- Addresses the challenges of drug development and precision medicine and suggests how to eliminate or mitigate these challenges through better utilization of biomarkers and diagnostics in drug development and patient management
- Features case studies and real-life examples from different classes of biomarkers on different platforms for different therapeutic areas and includes more than 200 illustrations
Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.
Über die Autorin bzw. den Autor
Dr Abdel B. Halim is an internationally-recognized key opinion leader with 25+ years of experience in different aspects of biomarkers, precision medicine and IVD; from strategic planning to actualization. He is the Vice president of Biomarkers and Companion Diagnostics at Taiho Oncology (Otsuka holding).
Before Taiho, Dr. Halim held multiple leadership positions in the pharmaceutical and diagnostic industries. He oversaw the development and validation of assays for several hundreds of biomarkers on different platforms and their applications in 150+ PI-PIII clinical trials and patient managements. Abdel has led 8 CDx programs and has track records for 5 FDA high complexity IVD approvals and 2 drug approvals. Abdel has served on 20+ governmental and public expert panels and advisory boards in the US, Canada and EU. Dr. Halim has served on 25+ committees to establish guidelines to promote quality in clinical laboratory and diagnostic industries and authored about 15 guidelines. Abdel has 70+ peer-reviewed publications, two book chapters and 100+ presentations including 40+ invited and keynote speeches in national and international meetings.
„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.
Neu kaufen
Diesen Artikel anzeigen
EUR 135,63
EUR 7,50 für den Versand von Vereinigtes Königreich nach USA
Versandziele, Kosten & DauerSuchergebnisse für Biomarkers, Diagnostics and Precision Medicine in the...
Beispielbild für diese ISBN
Biomarkers Diagnostics and Precision Medicine in the Drug Industry: Critical Challenges Limitations and Roadmaps for the Best Practices
Anbieter: Majestic Books, Hounslow, Vereinigtes Königreich
Verkäuferbewertung 5 von 5 Sternen
Zustand: New. pp. 294. Artikel-Nr. 369603851
Anzahl: 3 verfügbar
Beispielbild für diese ISBN
Biomarkers, Diagnostics and Precision Medicine in the Drug Industry: Critical Challenges, Limitations and Roadmaps for the Best Practices
Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes Königreich
Verkäuferbewertung 5 von 5 Sternen
Zustand: New. In. Artikel-Nr. ria9780128161210_new
Anzahl: Mehr als 20 verfügbar
Foto des Verkäufers
Biomarkers, Diagnostics and Precision Medicine in the Drug Industry: Critical Challenges, Limitations and Road Maps for the Best Practices
Anbieter: moluna, Greven, Deutschland
Verkäuferbewertung 5 von 5 Sternen
Zustand: New. Über den AutorrnrnDr Abdel B. Halim is an internationally-recognized key opinion leader with 25+ years of experience in different aspects of biomarkers, precision medicine and IVD from strategic planning to actualization. He is the Vice pr. Artikel-Nr. 254702814
Anzahl: Mehr als 20 verfügbar
Foto des Verkäufers
Biomarkers, Diagnostics and Precision Medicine in the Drug Industry : Critical Challenges, Limitations and Roadmaps for the Best Practices
Verlag:
Elsevier Science Publishing Co Inc Jun 2019, 2019
ISBN 10: 0128161213
ISBN 13: 9780128161210
Neu
Taschenbuch
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Verkäuferbewertung 5 von 5 Sternen
Taschenbuch. Zustand: Neu. Neuware - The high failure rate in the pharmaceutical industry has positioned biomarkers and personalized medicine in the frontline, as possible solutions. If executed right, biomarkers and companion diagnostics (CDx) can potentially help the drug industry enhance the probability of success, accelerate the time to market, and, more importantly, benefit patients by supporting accurate diagnosis and selection of the most effective and least toxic therapies. This book aims to examine the challenges and limitations in biomarkers and laboratory tests. It also offers advice on best practices to ensure proper application of biomarkers and bridges the gap between diagnostic business development claims and real-life deliverables. The book covers biomarkers for different purposes, provides examples from different technologies, which includes standard-of-care approved assays as well as for-investigational-use and for-research-use-only assays. It also includes new data for biomarkers in different therapeutic indications and offers case studies and practical examples. Artikel-Nr. 9780128161210
Anzahl: 2 verfügbar